BIOPROP20: biologically optimised IMRT for prostate radiotherapy in 20 fractions. Hypofractionated radiotherapy with intraprostatic boosts to tumour nodules in men with intermediate- and high-risk prostate cancer: a phase II trial – five-year outcomes
The Royal College of Radiologists Open（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要